Serum melatonin circadian profile in women suffering from the genital tract cancers

Neuroendocrinology Letters

Volumn 21, Issue 2, 2000, Pages 109-113

  Karasek, Michal ^a   Kowalski, Andrzej J ^a   Zylinska, Krystyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer; Circadian rhythms; Endometrial cancer; Female genital tract; Invasive ovarian cancer; Malignant tumors; Melatonin; Pineal gland; Squamous cervical cancer

Indexed keywords

MELATONIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HORMONE BLOOD LEVEL; HUMAN; NEUROENDOCRINOLOGY; OVARY CANCER; PINEAL BODY; RADIOIMMUNOASSAY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERUS MYOMA;

EID: 0034039736     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Blask DE. The pineal gland: an oncostatic gland. In: Reiter RJ, editor. Pineal gland. New York: Raven Press; 1984. p. 253-84.
2. Blask DE. Melatonin in oncology. In: Yu HS, Reiter RJ, editors. Melatonin. Biosynthesis, physiological effects, and clinical applications. Boca Raton: CRC Press; 1993. p. 447-75.
3. Karasek (1994) Malignant tumors and the pineal gland. In: Gupta D, Wollmann HA, Fedor-Freybergh P, editors. Patho-physiology of immune-neuroendocrine communication circuit. Heidelberg: Mattes; 1994. p. 225-44.
4. Karasek M. Relationship between the pineal gland and experimentally induced malignant tumors. Front Horm Res 1997; 23:99-106.
5. Karasek M, Pawlikowski M. Pineal gland, melatonin and cancer. Neuroendocrinol Lett 1999; 20:139-144.
6. Karasek M. Melatonin in human neoplastic disease. Int J Thymol 1996; 4(suppl. 1):75-79.
7. Bartsch C, Bartsch H, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981; 52:281-94.
8. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Cancer 1989; 64:426-33.
9. Bartsch C, Bartsch H, Bellman O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991; 67:1681-4.
10. Bartsch C, Bartsch H, Flüchter SH, Harzmann R, Attanasio A, Bichler KH, et al. Circadian rhythms of serum melatonin, prolactin and growth hormone in patients with benign and malignant tumours of the prostate and in non-tumor controls. Neuroendocrinol Lett 1983; 5:377-86.
11. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992; 209:153-76.
12. Khoory R, Stemme D. Plasma melatonin levels in patients suffering from colorectai carcinoma. J Pineal Res 1988; 5:251-8.
13. Karasek M, Dec W, Kowalski AJ, Bartsch H, Bartsch C. Serum melatonin circadian profile in women with adenocarcinoma of uterine corpus. Int J Thymol 1996; 4(suppl. 1):80-83.
14. Blask DE, Hill SM. Studies on MCF-7 human breast cancer cells in culture. J Neural Transm 1986; Suppl. 21:433-49.
15. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48:6121-6.
16. Persengiev SP, Kyurkchiev S. Selective effects of melatonin on the proliferation of lymphoid cells. Int J Biochem 1993; 25:441-4.
17. Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res 1993; 14:27-33.
18. Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 1993; 246:89-96.
19. Cos S, Verduga R, Fernandez-Viadero C, Megias M, Crespo D. Effects of melatonin on the proliferation and differentiation of human neuroblastoma cells in culture. Neurosci Lett 1996; 216:113-6.
20. Hu DN, Roberts JE. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res 1997; 7:27-31.
21. Lupowitz Z, Zisapel N. Hormonal interactions in human prostate tumor LNCaP cells. J Steroid Biochem Mol Biol 1999; 68:83-8.
22. Leone AM, Silman RE, Hill BT, Whelan RDH, Shellard SA. Growth inhibitory effects of melatonin and its metabolites against ovarian tumour cell lines in vitro. In: Gupta D, Attanasio A, Reiter RJ, editors. The pineal gland and cancer. London: Brain Research Promotion; 1938. p. 273-81.
23. Shellard SA, Whelan RDH, Hill BT. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. Br J Cancer 1989; 60:288-90.
24. Petranka J, Baldwin W, Biedermann J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999; 26:129-36.
25. Chen LD, Leal BZ, Reiter RJ, Abe M, Sewerynek E, Melchiori D, et al. Melatonin's inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione concentrations. Cancer Lett 1995; 91:153-9.
26. Skene D, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J. 6-Sulfatoxymelatonin production in breast cancer patients. J Pineal Res 1990; 8:269-75.
27. Karasek M, Kuzdak K, Cywinski J, Zylinska K, Smialowska A, Pluzanska A. Effects of melatonin administration in advanced breast cancer patients - preliminary report. Neuroendocrinol Lett 1998; 19:15-9.
28. Vician M, Zeman M, Herichova I, Jurani M, Blazicek P, Matis P. Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery. J Pineal Res 1999; 27:164-9.
29. Grin W, Grunberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest 1998; 45:62-5.
30. Hoffman PG, Siiteri PK. Sex steroid receptors in gynecologic cancer. Obstetr Gynecol 1980; 55:648-52.
31. Dietrich W. New aspect of steroid hormone dependent tumor growth. Arch Geschwulstforsch 1990; 60:149-60.
32. Miller WR, Langdon SP. Steroid hormones and cancer: (III) Observations from human subjects. Eur J Surg Oncol 1997; 23:163-83.
33. Jenster G. The role of the androger receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26:407-21.
34. Fujimoto J, Horose R, Sakaguchi H, Tamaya T. Estrogen dependency in uterine endometrial cancers. Oncology 1998; 55(suppl. 1):53-9.
35. Gadducci A, Fanucchi A, Cosio S, Genazzani AR. Hormone replacement therapy and gynecological cancer. Anticancer Res 1997; 17:3793-8
36. Shushan A, Paltiel O, Schenkler JG. Induction of ovulation and borderline ovarian cancer - the hormonal connections? Eur J Obstet Gynecol Reprod Biol 1999; 85:71-4.
37. Ciocca DR, Puy LA, Fasoli LC. Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cervix. Cancer Res 1989; 49:4298-304.